Table 1 Effect of serial dezamizumab doses in subjects with hepatic amyloidosis.

Median normal extracellular volume (ECV), 0.29; liver stiffness, 5.3 kPa (90% <7.0 kPa); GGT, γ-glutamyl transpeptidase, 5 to 45 IU/liter. These 10 subjects were those who had definite detectable hepatic amyloidosis. Subjects 011 and 013 entered clonal relapse after first dosing session. Subject 014 suffered clonal relapse after second dose and developed rash in session 3, thus receiving only half of the planned 1000-mg dose.

SubjectAmyloid typeDezamizumab
dose (mg)*
Amyloid load
by SAP scan
Liver ECV
predose
Liver ECV
day 42
Liver
stiffness
(kPa)
predose
Liver
stiffness
(kPa) day
42
GGT
(IU/liter)
predose
GGT
(IU/liter)
day 42
007AL152No change0.450.5010.49.89396
600No change0.400.438.45.97479
2000Liver and
spleen reduced
0.400.376.34.96667
008AL246Liver reduced0.370.3314.48.913598
600Spleen
reduced
0.300.245.78.94443
009AApoAI650Liver reduced0.480.4224.211.9714331
1000No change0.460.4417.88.9264278
2000Liver and
spleen reduced
0.400.4012.56.6283211
010AL400No change0.580.6146.525.7181158
1200No change0.610.6648.028.0166125
2000Liver reduced0.530.5627.316.912988
011AL650Liver reduced0.540.5327.015.7466411
1000No change0.580.6328.023.9401465
2000No change0.650.6335.327.0526751
013AL650Liver reduced0.360.295.72.82016
600Kidney
reduced
0.330.353.33.71418
Adrenal
reduced
014AL600Liver reduced0.350.348.94.414896
1000Liver reduced0.340.324.37.56044
500Liver increased0.310.324.84.83233
015AL600No change0.420.384.95.22719
2000Spleen
reduced
0.430.376.34.22418
016AL600No change0.450.4327.727.0274240
2000No change0.430.4035.317.3161126
2000Liver reduced0.360.3314.813.310677
019AL2000No change0.420.4326.632.06970

*Doses shown are as planned unless administered doses differed greatly.